AbbVie Inc. Goodwill and Intangible Assets (Total)

Goodwill and Intangible Assets (Total) of ABBV for past 10 years: annual, quarterly and twelve month trailing (TTM) including Goodwill and Intangible Assets (Total) growth rates and interactive chart. The sum of goodwill and all other intangible assets. Intangible assets are items that a company owns and derives benefit from, but is unable to physically measure and count. Examples of intangible assets include patents, trademarks and copyrights. Goodwill is a special type of intangible asset that normally appears in a company's balance sheet following a business combination. When the fair value of the consideration paid by the purchaser for an entity exceeds the fair value of the net assets they have acquired, the purchaser must recognize the resulting difference as goodwill in their balance sheet.

Highlights and Quick Summary

  • Goodwill and Intangible Assets (Total) for the quarter ending September 29, 2020 was $117 Billion (a -1.42% decrease compared to previous quarter)
  • Year-over-year quarterly Goodwill and Intangible Assets (Total) increased by 242.87%
  • Annual Goodwill and Intangible Assets (Total) for 2019 was $34.3 Billion (a -7.16% decrease from previous year)
  • Annual Goodwill and Intangible Assets (Total) for 2018 was $36.9 Billion (a -14.88% decrease from previous year)
  • Annual Goodwill and Intangible Assets (Total) for 2017 was $43.3 Billion (a -2.19% decrease from previous year)
Visit stockrow.com/ABBV for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Goodwill and Intangible Assets (Total) of AbbVie Inc.

Most recent Goodwill and Intangible Assets (Total)of ABBV including historical data for past 10 years.

Interactive Chart of Goodwill and Intangible Assets (Total) of AbbVie Inc.

AbbVie Inc. Goodwill and Intangible Assets (Total) for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 – $117,444.0 $119,132.0 $33,764.0 –
2019 $34,253.0 $34,573.0 $36,101.0 $36,452.0 $34,253.0
2018 $36,896.0 $42,343.0 $42,595.0 $43,110.0 $36,896.0
2017 $43,344.0 $43,915.0 $44,018.0 $44,119.0 $43,344.0
2016 $44,313.0 $44,770.0 $44,957.0 $32,786.0 $44,313.0
2015 $32,877.0 $33,065.0 $33,146.0 $7,012.0 $32,877.0
2014 $7,375.0 $7,542.0 $7,939.0 $8,073.0 $7,375.0
2013 $8,167.0 $8,192.0 $8,221.0 $8,213.0 $8,167.0
2012 $8,453.0 $8,523.26 $8,513.86 $8,908.7 $8,453.0
2011 $9,010.0 $0.0 $0.0 $0.0 $9,010.0
2010 $9,888.36 – – – $9,888.36

Business Profile of AbbVie Inc.

Sector: Healthcare
Industry: Drug Manufacturers—General
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the United States, Japan, Germany, Canada, France, Spain, Italy, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides SYNAGIS that protects at-risk infants from severe respiratory disease; KALETRA, a prescription anti-HIV-1 medicine; CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; and Lupron, a product for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; and Sevoflurane, an anesthesia product. It has collaborations with Calico Life Sciences LLC; Alector, Inc.; Janssen Biotech, Inc.; Frontier Medicines, Corp.; Jacobio Pharmaceuticals; I-Mab; and Genmab A/S. The company was incorporated in 2012 and is based in North Chicago, Illinois.
© stockrow.com